Several genes included in our signature, notably NOTCH1, NES, E2F1 and EGFR, have been implicated in glioma adaptation to temozolomide (TMZ) therapy, where changes in their expression or activity influence stemness, invasion and drug resistance [28,29,30]. This evidence concerns the gene E2F1 and central nervous system cancer.